Lung Cancer

Videos

Brigatinib Plus LCT Safe, Feasible for TKI-Naïve Patients With ALK+ NSCLC

05/31/2020

Yasir Elamin, MD, talks about the findings of a study in which LCT plus brigatinib was shown to be an effective treatment for ALK-rearranged advanced NSCLC.

Yasir Elamin, MD, talks about...

05/31/2020

Oncology

Videos

Experts Identify Mutational Biomarker for Poor Prognosis in ALK+ NSCLC

05/30/2020

David Carbone, MD, PhD, comments on a study in which a mutation was identified as a biomarker for poor prognosis in patients with ALK-positive NSCLC.

David Carbone, MD, PhD, comments...

05/30/2020

Oncology

Videos

Combining LCT and Brigatinib May Benefit Patients With ALK+ NSCLC

05/27/2020

David Carbone, MD, PhD, comments on a study evaluating the use of LCT plus brigatinib for patients with ALK-positive NSCLC.

David Carbone, MD, PhD, comments...

05/27/2020

Oncology

News

EZH2-Inhibitor Shows Activity in Relapsed/Refractory Malignant Mesothelioma

05/27/2020

Phase 2 trial data demonstrate the antitumor activity of tazemetostat in patients with BAP1-deficient relapsed or refractory malignant mesothelioma.

Phase 2 trial data demonstrate...

05/27/2020

Oncology

Videos

Pembrolizumab Added to Chemo Maintains OS, PFS Benefits in Metastatic NSCLC

05/27/2020

Yasir Elamin, MD, discusses the clinical significance of the KEYNOTE-189 clinical trial evaluating the use of chemo plus pembrolizumab for metastatic, nonsquamous NSCLC.

Yasir Elamin, MD, discusses the...

05/27/2020

Oncology

Videos

Fadi Braiteh, MD, Discusses the Ins and Outs of Entrectinib Therapy for NSCLC

12/03/2019

Dr Braiteh spoke in detail about the use of entrectinib therapy in patients with NSCLC at the 2019 Perspectives in Thoracic Oncology meeting.

Dr Braiteh spoke in detail about...

12/03/2019

Oncology

Videos

Second-Line Therapies in the Treatment of NSCLC